No Detail Found!

Efficacy of Vericiguat in patients with heart failure: A systematic review and meta- analysis of randomized controlled trials

Author(s)
Darmadi Darmadi Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan
Herwindo Ahmad Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan
Cennikon Pakpahan Department of Parasitology, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia
Sem Samuel Surja Department of Parasitology, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia
Abstract
Objective: This meta-analysis evaluates its efficacy and safety of Vericiguat, an oral soluble guanylate cyclase stimulator Methodology: A systematic search was conducted using PubMed, Scopus, and Cochrane databases through May 31, 2024. Randomized controlled trials (RCTs) comparing vericiguat to placebo in heart failure patients were included. Pooled risk ratios (RR) for cardiovascular death, heart failure hospitalization, and adverse events were calculated using a fixed-effects model. Risk of bias was assessed using the Cochrane ROB 2.0 tool. Results: Four RCTs comprising 3,564 patients were included, with overall low to unclear risk of bias. Vericiguat showed no statistically significant reduction in cardiovascular death (RR 0.90; 95% CI 0.75-1.07; p=0.23) or heart failure hospitalization (RR 0.92; 95% CI 0.85-1.01; p=0.06). Adverse event rates were similar between groups (RR 1.00; 95% CI 0.98-1.03; p=0.86). Conclusion: Vericiguat appears to be a well-tolerated treatment for heart failure; however, current evidence does not confirm significant clinical benefit in reducing cardiovascular death or hospitalizations. Further large-scale trials are warranted to clarify its therapeutic role.
Publication Details
Page(s) 825-830
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 50, Issue: 3, Year: 2025

Request the full text from PASTIC

Keywords
Efficacy, Heart failure, Safety., Meta-analysis, Vericiguat
References
Heidenreich PA,Bozkurt B,Aguilar D,Allen LA,Byun JJ,Colvin MM .2022 .AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol, 79 : e263-421.
Shahim B,Kapelios CJ,Savarese G,Lund LH .2023 .Global Public Health Burden of Heart Failure: An Updated Review. Card Fail Rev, 9 : e11.
Kesehatan Republik Indonesia Kementrian .2018 .. Laporan Nasional Riskesdas, : 182-3.
Fukuta H,Goto T,Wakami K,Ohte N. .2016 .Effects of drug and exercise intervention on functional capacity and quality of life in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. Eur J Prev Cardiol, 23 : 78-85.
Lewis EF,Kim HY,Claggett B,Spertus J,Heitner JF,Assmann SF .2016 .Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circ Heart Fail, 9 : e001937.
Stasch JP,Pacher P,Evgenov O V. P .2011 .Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation, 123 : 2263-73.
Armstrong PW,Roessig L,Patel MJ,Anstrom KJ,Butler J,Voors AA .2018 .Randomized, DoubleBlind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. JACC Heart Fail, 6 : 96-104.
Armstrong PW,Pieske B,Anstrom KJ,Ezekowitz J,Hernandez AF,Butler J .2020 .Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Eng J Med, 382 : 1883-93.
Filippatos G,Maggioni AP,Lam CSP,Pieske-Kraigher E,Butler J,Spertus J .2017 .Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. Eur J Heart Fail, 19 : 782-91.
Gheorghiade M,Greene SJ,Butler J,Filippatos G,Lam CSP,Maggioni AP .2015 .Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction the socrates-reduced randomized trial. J Am Med Assoc, 314 : 2251-62.
Pieske B,Maggioni AP,Lam CSP,Pieske-Kraigher E,Filippatos G,Butler J .2017 .Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: Results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES- PRESERVED) study. Eur Heart J, 38 : 1119-27.
Higgins JPT .2011 .. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, : .
Dzhioeva O,Belyavskiy E .2020 .Diagnosis and management of patients with heart failure with preserved ejection fraction (Hfpef): Current perspectives and recommendations. Ther Clin Risk Manag, 16 : 769-85.
Lin Y,Wu M,Liao B,Pang X,Chen Q,Yuan J .2021 .Comparison of Pharmacological Treatment Effects on LongTime Outcomes in Heart Failure With Preserved Ejection Fraction: A Network Meta- analysis of Randomized Controlled Trials. Front Pharmacol, 12 : 707777.
Li Q,Li Z,Li T,Wang Y,Feng J,Lu C .2021 .Efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. Pharmazie, 76 : 488-93.
Coats AJS .2020 .Vericiguat for heart failure and the VICTORIA trial - the dog that didn't bark?. Eur J Heart Fail, 22 : 576-7.
Aimo A,Pateras K,Stamatelopoulos K,Bayes-Genis A,Lombardi CM,Passino C .2021 .Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. Cardiovasc Drugs Ther, 35 : 1067-76.
Aimo A,Castiglione V,Vergaro G,Panichella G,Senni M,Lombardi CM .2022 .The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Fail Rev, 27 : 1165-71.
Tran BA,Serag-Bolos ES,Fernandez J,Miranda AC .2023 .Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction. J Pharm Pract, 36 : 905-14.
Follmann M,Ackerstaff J,Redlich G,Wunder F,Lang D,Kern A .2017 .Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. J Med Chem, 60 : 5146-61.
0

Citations

0

Downloads

51

Views